Drug Type Small molecule drug |
Synonyms Branched Chain Amino Acid |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Abdominal Pain | Phase 2 | US | 01 Jun 2021 | |
Brain Injury, Chronic | Phase 2 | US | 01 Jun 2021 | |
Diarrhea | Phase 2 | US | 01 Jun 2021 | |
Edema | Phase 2 | US | 01 Jun 2021 | |
Fibrosis | Phase 2 | US | 01 Jun 2021 | |
Hemorrhage | Phase 2 | US | 01 Jun 2021 | |
Hepatic Encephalopathy | Phase 2 | US | 01 Jun 2021 | |
Hepatic Infarction | Phase 2 | US | 01 Jun 2021 | |
Hepatocellular Carcinoma | Phase 2 | US | 01 Jun 2021 | |
Hypertension | Phase 2 | US | 01 Jun 2021 |
Not Applicable | 37 | BCAA granules 4.15 grams thrice daily | jdotxiswoa(ztijwfvvta) = ccwgznzthr fsqbmmfqtf (smphghegpl ) | - | 23 Jun 2022 | ||
Placebo | jdotxiswoa(ztijwfvvta) = axlujpdczs fsqbmmfqtf (smphghegpl ) | ||||||
Phase 4 | 827 | gxvyxeyqqa(opbyjpuioc): RR = 0.73 (95% CI, 0.61 - 0.88) | - | 18 May 2017 | |||
(Control intervention) | |||||||
Phase 4 | 646 | BCAA orally administered at 12 g/day | bsjxnxcxsd(atjoadxmmk): hazard ratio = 0.67 (95% CI, 0.49 - 0.93) | - | 01 Jul 2005 | ||
diet therapy with defined daily food intake | |||||||
Phase 4 | 8 | (BCAA supplements in the late evening) | mmmgpeytmt(nrryrslola) = The frequency of muscle cramps decreased (7.4+/-2.0 vs. 0.3+/-0.5 times/week, P<0.0001) dramatically. weppfhxhat (ymrjedqbrp ) | - | 01 Aug 2003 | ||
Phase 4 | 174 | uwvxslojnf(oszorcoifz) = decreased iwgvegvwlo (esaihtqcad ) View more | Positive | 01 Jun 2003 | |||
Lactoalbumin |